Revvity Inc.

Revvity raised its full-year 2026 guidance, now expecting total company organic growth of 4% to 5% and adjusted earnings per share of $5.30 to $5.40, up from its prior outlook of 3% to 4% growth and $5.20 to $5.30. The company reported second-quarter pro forma organic growth of 3% on total revenue of $711 million, with adjusted EPS of $1.41 well above the high end of its guidance, driven partly by $16 million in tariff-related refunds and favorable tax timing. Diagnostics revenue grew 11% organically to $352 million, while Life Sciences revenue declined 3% organically to $359 million, weighed down by an approximately 20% decline in Signals software. Management cited a progressively larger increase in orders directly related to AI and a higher-than-normal instrument backlog exiting the quarter, with double-digit growth in high-content screening. The company also signed a definitive agreement for the divestiture of its China immunodiagnostics business, expected to close by the end of 2027.

Revvity announced the development of the T-SPOT A201, a next-generation high-throughput automated platform for latent tuberculosis testing targeted for launch in the second half of 2027. The platform is designed to process up to 384 samples per instrument during an eight-hour shift with only 45 seconds of hands-on time per sample, building on the success of the Auto-Pure 2400 liquid handler. Revvity shares gained 2.4% following the announcement, and the stock has risen 16.9% year to date, outperforming the industry's 1.8% decline and the S&P 500's 7.4% gain. The U.S. tuberculosis diagnostics market is predicted to be valued at $607.5 million in 2026 and grow at a CAGR of 5.3% through 2035, according to Precedence Research. Revvity currently carries a Zacks Rank of 5, or Strong Sell.

The global high-throughput screening market is projected to grow from USD 27.66 billion in 2026 to USD 45.90 billion by 2031, at a compound annual growth rate of 10.7 percent, according to a new report from MarketsandMarkets. Growth is driven by rising pharmaceutical and biotechnology R&D investments, increasing adoption of automated drug discovery platforms, and technological advances in areas such as cell-based screening and artificial intelligence-enabled analytics. The products segment accounted for the largest share of the market in 2025, with reagents, kits and consumables being the largest product type due to their recurring use across screening workflows. Asia Pacific is expected to register the highest growth rate during the forecast period, supported by expanding research activities and growing contract research organization presence in countries including China, India, Japan, and South Korea. Key players in the market include Thermo Fisher Scientific, Agilent Technologies, Merck KGaA, Danaher Corporation, and Revvity, with the top participants collectively holding approximately 38 percent of the global market.

The South Korea automated liquid handling system market is projected to grow from $23.5 million in 2025 to $51.0 million by 2036, at a compound annual growth rate of 7.47%. The automated liquid handling system segment is expected to dominate by type, while liquid handling workstations lead by product. Drug discovery is the leading application, and pharmaceutical and biotechnology companies are the primary end users. Key players include Agilent Technologies, Revvity, Thermo Fisher Scientific, Danaher, and Tecan Group.

Revvity has launched Signals AI, a native agentic framework embedded within its Signals One platform that lets scientists interact with R&D data using natural language. The tool transforms experimental, instrument, and system-generated data into insights and actionable outcomes, combining modern AI reasoning with domain-specific ontologies and validated algorithms to deliver traceable, context-aware responses. Select capabilities are available now, with further enhancements expected in the coming weeks. Revvity shares fell 1% on the day of the announcement, though the stock is up 2.3% year-to-date against a 7.8% decline for its industry.